Changeflow GovPing Healthcare & Life Sciences Pyrimidine Derivatives Inhibit c-Kit Kinase for...
Routine Notice Added Final

Pyrimidine Derivatives Inhibit c-Kit Kinase for Cancer Treatment

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

Merck Patent GmbH has filed US Patent Application US20260109697A1, published April 23, 2026, covering 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives as inhibitors of c-Kit kinase for cancer treatment. The application, filed October 30, 2025 (Application No. 19373991), names inventors Dieter Dorsch, Andreas Blum, and Hans-Peter Buchstaller. CPC classifications span C07D 471/04, A61K 31/506, and related pharmaceutical compound categories.

“Compounds of the formula I are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification C07D covers heterocyclic organic compounds: the chemical core of most small-molecule drugs, including kinase inhibitors, GLP-1 receptor agonists, antibiotics, antivirals, and CNS therapies. Every newly published application in C07D lands in this feed, around 160 a month. Applications publish 18 months after filing, so this feed reveals what medicinal chemistry groups at Pfizer, Novartis, Roche, Shionogi, and others were synthesizing in the prior year and a half. Watch this if you run a medicinal chemistry program, file patent clearance for new drug candidates, scout competitor pipelines before clinical readouts, or track heterocyclic innovation across therapeutic areas.

What changed

Merck Patent GmbH has published US Patent Application US20260109697A1, a published patent application for 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives as c-Kit kinase inhibitors for cancer treatment. The application was filed October 30, 2025, and published April 23, 2026, listing inventors Dieter Dorsch, Andreas Blum, and Hans-Peter Buchstaller. The compounds of formula I are claimed as inhibitors of c-Kit kinase for the treatment of cancer, with R1, R2, R3, V, X, Y, and Z substituents defined across multiple substitution patterns.

For parties monitoring competitive IP landscapes in oncology therapeutics, this published application establishes a priority date of October 30, 2025. Competitors developing c-Kit inhibitor programs should assess potential freedom-to-operate implications. This document is a published patent application, not a granted patent — it represents a pending claim under examination rather than an issued enforceable right.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES

Application US20260109697A1 Kind: A1 Apr 23, 2026

Assignee

Merck Patent GmbH

Inventors

Dieter Dorsch, Andreas Blum, Hans-Peter Buchstaller

Abstract

Compounds of the formula I are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer. R1 denotes H, Hal, CF3, NO2, A, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, OR3, O[C(R3)2]nN(R3)2, O[C(R3)2]nS(O)mR3, O[C(R3)2]COOR3, O[C(R3)2]˜COON(R3)2, O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, O[C(R3)2]nPh, or O[C(R3)2]nCyc. R2 denotes H or CH3. R3 denotes H or A. V denotes H or Hal. X denotes O or N(R3). Y denotes phenylene, pyridin-diyl, thiophen-diyl, 1,3-thiazol-diyl or pyrazol-diyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal and/or A. Z denotes CON(R3)2, phenyl, Het4 or —O-A.

CPC Classifications

C07D 471/04 A61K 31/506 A61K 31/5377 A61K 31/541 A61K 45/06 C07D 239/42 C07D 403/12 C07D 519/00

Filing Date

2025-10-30

Application No.

19373991

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Kinase inhibitor research Cancer therapeutics
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!